Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Brain Tumor Pathology
Published in: Brain Tumor Pathology 4/2017

01-10-2017 | Original Article

Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors

Authors: Akane Suzuki, Takashi Maruyama, Masayuki Nitta, Takashi Komori, Soko Ikuta, Takakazu Kawamata, Yoshihiro Muragaki

Published in: Brain Tumor Pathology | Issue 4/2017

Login to get access

Abstract

Rapid immunohistochemistry (R-IHC) has been developing mainly as a support technique in the rapid diagnosis of central nervous system tumors; however, there have been problems regarding instability in specimen preparation and immunostaining. To overcome the weakness of this technology, the instability of immunostaining, we developed a modified R-IHC. This was achieved by switching to 4% paraformaldehyde as the fixative solution and utilizing a commercially available Polymer Refine Detection Kit, as a high-sensitivity kit, in place of the secondary antibodies. In this study, we tested the modified R-IHC by evaluating rapid immunostaining on new staining items in 94 brain tumor removal cases, which took place at Tokyo Women’s Medical University from 2014 to 2015. The results showed that, based on GFAP and p53 markers, the modified method obtained a higher stability in specimens than the standard rapid immunostaining method. It also achieved stainability on the same level as that of a permanent specimen. The modified method tested 86.6% (46/53) and 82.8% (24/29) in pHH3 and ATRX, respectively, in the percentage of correct classification (PCC) against the permanent specimens, and 100% (7/7) in the PCC against malignant lymphomas and gliomas that used CD20/CD3 for discrimination. We concluded that the modified R-IHC method indicated a higher stainability and PCC against the permanent specimens in comparison to the standard method in GFAP, p53, CD20/CD3, pHH3, and ATRX.
Literature
1.
Plesec TP, Prayson RA (2007) Frozen section discrepancy in the evaluation of central nervous system tumor. Arch Pathol Lab Med 131(10):1532–1540PubMed
2.
Uematsu Y, Owai Y, Okita R, Tanaka Y, Itakura T (2007) The usefulness and problem of intraoperative rapid diagnosis in surgical neuropathology. Brain Tumor Pathol 24(2):47–52CrossRefPubMed
3.
Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P, Ellison DW (2016) The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol 131(6):803–820CrossRefPubMed
4.
Masui K, Mischel PS, Reifenberger G (2016) Molecular classification of gliomas. Handb Clin Neurol 134:97–120CrossRefPubMed
5.
Kannan K, Inagaki A, Silber J, Gorovets D, Zhang J, Kastenhuber ER, Heguy A, Petrini JH, Chan TA, Huse JT (2012) Whole-exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma. Oncotarget 3(10):1194–1203CrossRefPubMedPubMedCentral
6.
Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, Ichimura K (2013) Upregulating mutations in the TERT promoter commonly occur in adult malignant gliomas and are strongly associated with total 1p19q loss. Acta Neuropathol 126(2):267–276CrossRefPubMed
7.
Hartmann C, Hentschel B, Wick W, Capper D, Felsberg J, Simon M, Westphal M, Schackert G, Meyermann R, Pietsch T, Reifenberger G, Weller M, Loeffler M, von Deimling A (2010) Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol 120(6):707–718CrossRefPubMed
8.
Kurimoto M, Suzuki H, Aoki K, Ohka F, Kondo G, Motomura K, Iijima K, Yamamichi A, Ranjit M, Wakabayashi T, Kimura S, Natsume A (2016) Rapid sensitive analysis of IDH1 mutation in lower-grade gliomas by automated genetic typing involving a quenching probe. Cancer Invest 34(1):12–15CrossRefPubMed
9.
Haapasalo J, Mennander A, Helen P, Haapasalo H, Isola J (2005) Ultrarapid Ki-67 immunostaining in frozen section interpretation of gliomas. J Clin Pathol 58(3):263–268CrossRefPubMedPubMedCentral
10.
Denda T, Kamoshida S, Kawamura J, Harada K, Kawai K, Kuwao S, Sawabe M (2013) Rapid immunocytochemistry with simple heat-induced antigen retrieval technique for improvement in the quality of cytological diagnosis. J Histochem Cytochem 61(12):920–930CrossRefPubMedPubMedCentral
11.
Hatta H, Tsuneyama K, Kondo T, Takano Y (2010) Development of an ultrasound-emitting device for performing rapid immunostaining procedures. J Histochem Cytochem 58(5):421–428CrossRefPubMedPubMedCentral
12.
Kanamori M, Kikuchi A, Watanabe M, Shibahara I, Saito R, Yamashita Y, Sonoda Y, Kumabe T, Kure S, Tominaga T (2014) Rapid and sensitive intraoperative detection of mutations in the isocitrate dehydrogenase 1 and 2 genes during surgery for glioma. J Neurosurg 120(6):1288–1297CrossRefPubMed
13.
Shioyama T, Muragaki Y, Maruyama T, Komori T, Iseki H (2013) Intraoperative flow cytometry analysis of glioma tissue for rapid determination of tumor presence and its histopathological grade: clinical article. J Neurosurg 118(6):1232–1238CrossRefPubMed
14.
15.
Tanino M, Sasajima T, Nanjo H, Akesaka S, Kagaya M, Kimura T, Ishida Y, Oda M, Takahashi M, Sugawara T, Yoshioka T, Nishihara H, Akagami Y, Goto A, Minamiya Y, Tanaka S, R-IHC Study Group (2015) Rapid immunohistochemistry based on alternating current electric field for intraoperative diagnosis of brain tumors. Brain Tumor Pathol 32(1):12–19CrossRefPubMed
16.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 111:97–109CrossRef
17.
Terata K, Saito H, Nanjo H et al (2017) Novel rapid-immunohistochemistry using an alternating current electric field for intraoperative diagnosis of sentinel lymph nodes in breast cancer. Sci Rep 7:2810CrossRefPubMedPubMedCentral
18.
Toda H, Minamiya Y, Kagaya M et al (2011) A novel immunohistochemical staining method allows ultrarapid detection of lymph node micrometastases while conserving antibody. Acta Histochem Cytochem 44(3):133–139CrossRefPubMedPubMedCentral
19.
Varughese RK, Lind-Landström T, Habberstad AH, Salvesen Ø, Haug CS, Sundstrøm S, Torp SH (2016) Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. J Clin Pathol 69(1):26–34CrossRefPubMed
20.
Wiestler B, Capper D, Holland-Letz T, Korshunov A, von Deimling A, Pfister SM, Platten M, Weller M, Wick W (2013) ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis. Acta Neuropathol 126(3):443–451CrossRefPubMed
21.
Zhang J, Wu G, Miller CP, Tatevossian RG, Dalton JD, Baker SJ, Ellison DW et al; St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project (2013) Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat Genet 45(6):602–612
22.
Tabouret E, Nguyen AT, Dehais C, Carpentier C, Ducray F, Idbaih A, Mokhtari K, Jouvet A, Uro-Coste E, Colin C, Chinot O, Loiseau H, Moyal E, Maurage CA, Polivka M, Lechapt-Zalcman E, Desenclos C, Meyronet D, Delattre JY, Figarella-Branger D, Network For POLA (2016) Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. Acta Neuropathol 132(4):625–634CrossRefPubMed
23.
Zhang C, Moore LM, Li X, Yung WK, Zhang W (2013) IDH1/2 mutations target a key hallmark of cancer by deregulating cellular metabolism in glioma. Neurooncology 15(9):1114–1126
Metadata
Title
Modified rapid immunohistochemical staining for intraoperative diagnosis of malignant brain tumors
Authors
Akane Suzuki
Takashi Maruyama
Masayuki Nitta
Takashi Komori
Soko Ikuta
Takakazu Kawamata
Yoshihiro Muragaki
Publication date
01-10-2017
Publisher
Springer Singapore
Published in
Brain Tumor Pathology / Issue 4/2017
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI
https://doi.org/10.1007/s10014-017-0293-9

Other articles of this Issue 4/2017

Brain Tumor Pathology 4/2017 Go to the issue

Editorial

Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology

Case Report

Long-term epilepsy-associated tumor in the amygdala of a 16-year-old boy: report of a rare case having intranuclear filaments

Letter to the Editor

Expression of large neutral amino acid transporters LAT1 and LAT2 in medulloblastoma

Case Report

Encouraging option of multi-staged gross total resection for a C11orf-RelA fusion-positive supratentorial anaplastic ependymoma

Original Article

Radiation-induced gliomas: a report of four cases and analysis of molecular biomarkers

Rapid Short Communication

Downregulation of SMARCB1/INI1 expression in pediatric chordomas correlates with upregulation of miR-671-5p and miR-193a-5p expressions